Using the SCD1 inhibitor CAY10566 or silencing SCD1 via CRISPR/Cas9 technology can delay tumor growth, reduce the formation of cancer stem cells, and decrease resistance to platinum-based drugs. This evidence concerns the gene SCD and cancer.